Hepatitis C: an economic evaluation of extended treatment with interferon

---

• 1.
• 2.
• 2. Garcia de Ancos JL, Roberts JA, Dusheiko GM. An economicevaluation of the costs of a-interferon treatment for chronic activehepatitis due to hepatitis B or C virus. J Hepatol 1990; 11:S11-S18.
• 3.
• Shiell A, Briggs A, Farrell G. The cost-effectiveness of alphainterferon in the treatment of chronic active hepatitis C. Med JAust 1994; 160: 268-272.
• 4.
• Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitiswith interferon alfa: an economic appraisal. Hepatology1995; 22: 1863-1873.
• 5.
• Joliet E, Vanlemmens C, Kerleau M, et al. Cost-effectivenessanalysis of the treatment of chronic hepatitis C. GastroenterolClin Biol 1997; 21: 336-338.
• 6.
• Bennet WG, Inoue Y, Beck R, et al. Estimates of thecost-effectiveness of a single course of interferon-a 2b in patientswith histologically mild hepatitis C. Ann Intern Med 1997;127: 855-865.
• 7.
• Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and12 months of interferon-a therapy for chronic hepatitis C. AnnIntern Med 1997; 127: 866-874.
• 8.
• National Institutes of Health Consensus Development Panelstatement: management of hepatitis C. Hepatology 1997; 26(3Suppl 1): 2S-10S.
• 9.
• Fattovitch G, Giustina G, Degos F, et al. Morbidity and mortality incompensated cirrhosis type C: a retrospective follow-up study of 384patients. Gastroenterology 1997; 112: 463-472.
• 10.
• Australian Bureau of Statistics. Deaths: Australia 1994.Canberra: ABS, 1994. (Catalogue No. 3302.0.)
• 11.
• Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferonrandomized trials in the treatment of viral hepatitis C: effects ofdose and duration. Hepatology 1996; 24: 778-789.
• 12.
• Carithers RL Jr, Sugano D, Bayliss M. Health assessment forchronic HCV infection: results of quality of life. Dig Dis Sci1996; 41: 75S-80S.
• 13.
• Davis GL, Balart LA, Schiff ER, et al. Assessing health-relatedquality of life in chronic hepatitis C using the Sickness ImpactProfile. Clin Ther 1994; 16: 334-343.
• 14.
• Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virusinfection causes a significant reduction in quality of life in theabsence of cirrhosis. Hepatology 1998; 27: 209-212.
• 15.
• National Health and Medical Research Council. A strategy for thedetection and management of hepatitis C in Australia. Canberra:NHMRC/AGPS, 1997.
• 16.
• Commonwealth Department of Health and Family Services. MedicalBenefits Schedule. Nov 1996. Canberra; AGPS, 1996.
• 17.
• Commonwealth Department of Health, Housing, Local Governmentand Community Services. Manual of Resource Items and theirAssociated Costs. Canberra: AGPS, November 1993.
• 18.
• Drummond MF, Brandt A, Luce B, Rovira J. Standardisingmethodologies for economic evaluation in health care. Int JTechnol Assess Health Care 1993; 9: 26-36.
• 19.
• Gold MR, Siegel JE, Russell LB, Weinstein MC, editors.Cost-effectiveness in health and medicine. New York: OxfordUniversity Press, 1996: 230.
• 20.
• AHMAC Breast Cancer Screening Evaluation Committee. Breastscreening in Australia: future directions. Canberra: AustralianInstitute of Health and Welfare, 1990.
• 21.
• AHMAC Cervical Cancer Screening Evaluation Committee. CervicalScreening in Australia: options for change. Canberra: AustralianInstitute of Health and Welfare, 1991.
• 22.
• Salkeld G, Davey PD, Arnolda G. A critical review ofhealth-related economic evaluations in Australia: implicationsfor health policy. Health Policy 1995; 31: 111-125.
• 23.
• Birch S, Donaldson C. Cost-benefit analysis: dealing with theproblems of indivisible projects and fixed budgets. HealthPolicy 1987; 7: 61-72.
• 24.
• Bennet WG, Pauker SG, Davis GL, Wong JB. Modeling therapeuticbenefit in the midst of uncertainty: therapy for hepatitis C. DigDis Sci 1996; 41: 56S-62S.
• 25.
• Koff RS, Seeff LB. Economic modeling of treatment of chronichepatitis B and chronic hepatitis C: promises and limitations.Hepatology 1995; 22: 1880-1885.
• 26.
• Owens DK. In the eye of the beholder: assessment of health-relatedquality of life. Hepatology 1998; 27: 292-293.